Article
Glioblastoma cellular cross-talk converges on NF-κB to attenuate EGFR inhibitor sensitivity.
Genes & development - 15 Jun 2017
Zanca Ciro, Villa Genaro R, Benitez Jorge A, Thorne Amy Haseley, Koga Tomoyuki, D'Antonio Matteo, Ikegami Shiro, Ma Jianhui, Boyer Antonia D, Banisadr Afsheen, Jameson Nathan M, Parisian Alison D, Eliseeva Olesja V, Barnabe Gabriela F, Liu Feng, Wu Sihan, Yang Huijun, Wykosky Jill, Frazer Kelly A, Verkhusha Vladislav V, Isaguliants Maria G, Weiss William A, Gahman Timothy C, Shiau Andrew K, Chen Clark C, Mischel Paul S, Cavenee Webster K, Furnari Frank B
Abstract excerpt
In glioblastoma (GBM), heterogeneous expression of amplified and mutated epidermal growth factor receptor (EGFR) presents a substantial challenge for the effective use of EGFR-directed therapeutics. Here we demonstrate that heterogeneous expression of the wild-type receptor and its constitutively active mutant form, EGFRvIII, limits sensitivity to these therapies through an interclonal communication mechanism...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.